TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Yiling Pharmaceutical makes the journey from small clinic to big pharma
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
S
hijiazhuang Yiling Pharmaceutical, a high-technology pharmaceutical company offering traditional Chinese medicine, has entered its third decade of business, once again proving the essentiality of traditional healthcare methods amid medical modernization.
The company was founded in 1992 by Professor Wu Yiling, a prominent member of the China Academy of Engineering. Wu’s leadership, vision and five-year plan has contributed to the success and growth of the company, transforming it into one of China’s 500 Most Valuable Brands, Top 20 Registered Pharmaceutical Companies in China and the Top 10 Chinese Drug Companies in China.
"Our company culture has inherent innovations that can benefit mankind’s welfare and aim at developing science and technology for a healthier future”, said executive vice president Zhang Yunling in a statement. She added, “We also focus on building enterprise competitiveness and conduct many scientific research projects through theoretical innovation on medical treatment and traditional drugs.”
What sets the company apart may be the right mixture of traditional methods and technology. Zhang revealed that developments focused on the health industry based on healthy technology innovation systems, market formulation, technology-based development strategies and carrying out scientific research. In addition, the company also had several development projects and was establishing national marketing networks.
The Shijiazhuang Yiling Pharmaceutical of today is a certified enterprise, both at the national and international level. The company meets medical standards applied in the United States, the European Union, Canada, New Zealand and several other countries.
While traditional Chinese methods of healing has been around for more than 3,000 years, Shijiazhuang Yiling Pharmaceutical leads traditional medication development, both academically and using Chinese medicine collateral theory, which integrates innovation, clinical medication and scientific research and development in Chinese medicine.
“Its innovative medical benefits are not only recognized worldwide, but also have a scientific certification basis. The medical industry has gradually acknowledged the existence of traditional medicine in international medical communities,” said Zhang. What is considered as national cultural heritage has had a prominent place in the healthcare industry around the world, with some choosing the method over Western medicine.
Shijiazhuang Yiling Pharmaceutical Co.Ltd also plays a major role in community welfare, providing assistance by donating Lianhua Qingwen capsules valued at 15 million yuan (US$2.17 million) to the Red Cross Society of China and Wuhan city during the pandemic.
In January 2021, the pharmaceutical company invested 50 million yuan in the Red Cross Society of China to fund projects related to COVID-19 aimed at providing medical support, epidemic prevention and normalization post pandemic efforts.
Outside of China, they have also donated 15 million yuan-worth of capsules to Thailand, Cambodia, Iraq, Italy, Nepal, Ecuador, Brazil and other countries as well as to international organizations to support local epidemic mitigation.
